+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 121 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating molnupiravir, a study medicine designed to stop the COVID-19 virus from multiplying, to see if it can prevent severe illness from COVID-19 more effectively than a placebo in people who are at high risk. The focus is on non-hospitalized adults with COVID-19 who have certain health conditions or factors that increase their chance of severe illness, which can require hospitalization or lead to death. Participants will be randomly assigned to receive either 800 mg of molnupiravir orally every 12 hours for 5 days a total of 10 doses or a matching placebo on the same schedule. Some participants may also receive remdesivir as standard care if clinically appropriate. This is a phase 3, double-blind, placebo-controlled study comparing molnupiravir versus placebo. During the study, participants will be monitored for up to 29 days for outcomes such as hospitalization, death, and COVID-19-related medically attended visits. Researchers will assess adverse events and discontinuation due to side effects over approximately 5 months. Other measures include tracking symptom relief, changes in virus levels, and need for medical interventions. The total participation duration covers treatment and follow-up monitoring to evaluate safety and effectiveness.

Age: 18Years +All GendersPhase 3
227 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are studying the safety, tolerability, and how LY3962681 behaves in the body pharmacokineticspharmacodynamics in healthy volunteers and patients with Parkinsons disease. The trial has two parts a Single Ascending Dose SAD study with healthy volunteers and a Multiple Ascending Dose MAD study with Parkinsons patients. This study is a Phase 1, randomized, double-blind, placebo-controlled trial sponsored by Prevail Therapeutics. In the SAD part, healthy volunteers receive a single intrathecal into spinal fluid dose of LY3962681 or placebo artificial cerebrospinal fluid. In the MAD part, Parkinsons patients receive two intrathecal doses of LY3962681 or placebo spaced 12 to 24 weeks apart. The SAD treatment period lasts one day, while the MAD treatment includes two dosing days spaced several months apart. Participants will undergo safety and tolerability assessments over follow-up periods up to 52 weeks after dosing. Evaluations include monitoring for serious and treatment-emergent adverse events, measuring drug levels in the body, and assessing changes in cerebrospinal fluid biomarkers related to Parkinsons disease. The total study duration may extend for up to 76 weeks, including treatment and follow-up phases.

Age: 30Years - 80YearsAll GendersPhase 1
16 locations
E

Actively Recruiting

Researchers are conducting a Phase 1, first in human, open-label trial to evaluate ALX2004, an antibody drug conjugate targeting EGFR, in participants with advanced or metastatic selected solid tumors. The study focuses on patients with non-small cell lung cancer NSCLC, head and neck squamous cell carcinoma HNSCC, esophageal squamous cell carcinoma ESCC, and colorectal cancer CRC who have received prior treatments. This research aims to assess the safety, dosing, and effectiveness of ALX2004 in these advanced cancers. The study includes three phases Phase 1a dose escalation to find safe dose levels, dose exploration to refine dosing in specific tumor types, and Phase 1b dose expansion where participants receive the recommended phase 2 dose. ALX2004 is administered by intravenous infusion. Participants will be enrolled sequentially into escalating dose levels initially, followed by enrollment into selected dose levels for further evaluation. Participants will undergo assessments for dose limiting toxicities, adverse events, and tumor response using RECIST criteria up to two years after dosing. Pharmacokinetics including drug concentration and clearance will be measured along with immunogenicity and survival outcomes. The study involves monitoring safety and treatment effects over time, with expected enrollment of up to 170 patients and a study duration extending to late 2027.

Age: 18Years +All GendersPhase 1
12 locations
M

Actively Recruiting

Healthy Volunteer

Researchers are conducting a Master Protocol study focusing on the safety and tolerability of multiple amyloid-targeting drugs in both healthy adults and individuals diagnosed with Alzheimers disease AD. This study aims to evaluate if these drugs can remove amyloid plaque, clumps of protein in the brain linked to AD. Participants will enroll in one of two substudies, either A1D-MC-AT01 or the upcoming A1D-MC-AT02, to assess these treatments. The study involves administering the drug LY4405094 or a placebo either intravenously IV or subcutaneously SC to healthy volunteers and AD participants. Participants with AD will also undergo amyloid positron emission tomography PET scans using Florbetapir F18 or Florbetaben F18 injected intravenously to help monitor amyloid plaque in the brain. The study uses a randomized, double-blind design and includes several substudies depending on participant health status. Participants will be closely monitored throughout the study period, which lasts up to 160 days from baseline. Evaluations include medical exams, electrocardiograms ECGs, cognitive assessments such as the Mini-Mental State Exam MMSE, and brain imaging with PET scans and magnetic resonance imaging MRI. Study partners will assist participants with Alzheimers disease by providing support and consent. Researchers will track the number of participants assigned to each substudy and assess safety and tolerability during the trial.

Age: 18Years - 85YearsAll GendersPhase 1
18 locations
P

Actively Recruiting

Researchers are evaluating HMBD-501, a HER3-targeted antibody-drug conjugate, in patients with advanced, relapsed, or refractory HER3-expressing solid tumors including melanoma, non-small cell lung cancer, and breast cancer. This Phase 12 trial aims to assess the safety, tolerability, how the drug moves in the body, and early signs of effectiveness. The study is sponsored by Hummingbird Bioscience and includes two parts a dose escalation phase followed by a dose expansion phase. During Phase 1, patients receive increasing doses of HMBD-501 by intravenous injection every three weeks to find the recommended dose for Phase 2. In Phase 2, patients receive this recommended dose to further evaluate the drugs preliminary clinical effects. The dose escalation helps identify the safest and most effective dose schedule for treating these advanced tumors. Participants will have regular visits for treatment, monitoring, and assessments including safety checks and blood tests to measure drug levels. The main outcomes include tracking any side effects during Phase 1 and measuring tumor responses in Phase 2 over about six months. Researchers will also study how the drug behaves in the body and monitor disease control and progression. Participants must follow the visit schedule and study procedures throughout the trial.

Age: 18Years +All GendersPhase 1Phase 2
7 locations
E

Actively Recruiting

Researchers are studying the safety and effectiveness of NEU-411 in people aged 40 to 80 years with early Parkinsons Disease PD who have a specific genetic profile that predicts increased activity in the LRRK2 pathway. This Phase 2 study uses a companion diagnostic genetic test to identify participants with LRRK2-driven PD. The trial aims to compare NEU-411, a brain-penetrant drug that inhibits LRRK2 activity, to a placebo. Participants will be randomly assigned to receive either NEU-411 30 mg once daily or a matching placebo for 52 weeks. After this double-blind treatment period, there will be a safety follow-up visit within two weeks. Those who qualify may continue into an open-label extension phase where they will receive NEU-411 for an additional 26 weeks. Throughout the study, participants will have their Parkinsons symptoms and safety monitored using digital biomarker scores and clinical rating scales. Researchers will assess changes from baseline in the Roche digital biomarker score and the Unified Parkinsons Disease Rating Scale over the 52-week treatment period. Safety will be tracked by recording adverse events through the end of the study. Total participation may last up to 78 weeks including the extension and follow-up.

Age: 40Years - 80YearsAll GendersPhase 2
72 locations
P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of divarasib combined with pembrolizumab compared with pembrolizumab plus pemetrexed and carboplatin or cisplatin for adults with KRAS G12C-mutated, advanced or metastatic non-squamous non-small cell lung cancer NSCLC who have not received prior treatment. This phase 3 randomized study aims to find the best first-line therapy option for this specific lung cancer type. Participants are randomly assigned to one of two groups one group receives divarasib orally once daily and pembrolizumab through intravenous infusion every three weeks, while the other group receives pembrolizumab, pemetrexed, and carboplatin or cisplatin all by intravenous infusion every three weeks. The study treatments are given as first-line therapy, and participants are monitored for up to approximately five years. During the study, participants undergo regular assessments including scans to measure tumor response, evaluations of lung cancer symptoms like cough and breathlessness, quality of life questionnaires, and monitoring for side effects. Researchers track progression-free survival and overall survival for up to about five years. Safety and symptom severity are closely followed throughout the study, providing comprehensive data on treatment impact and participant well-being.

Age: 18Years +All GendersPhase 3
288 locations
L

Actively Recruiting

Researchers are evaluating the long-term safety of buntanetap in adults aged 40 to 85 years with Parkinsons Disease PD. This open-label study lasts 36 months and includes two groups participants previously involved in buntanetap trials and those receiving deep brain stimulation DBS treatment. The study aims to monitor safety outcomes and adverse events associated with buntanetap over this period. Participants receive buntanetap capsules 30 mg orally once daily after a screening period of up to 42 days. Cohort 1 includes invited participants who have taken buntanetap before, while Cohort 2 consists of PD patients treated with DBS for at least one year. During clinic visits, participants in Cohort 1 stop PD medications 12 hours prior to baseline and annual assessments to achieve an OFF state, and Cohort 2 participants do the same before all visits, returning DBS settings to baseline the night before. Throughout the study, participants undergo assessments including cognitive tests MMSE, MoCA, suicide risk evaluation C-SSRS, and Parkinsons disease rating scales MDS-UPDRS administered by trained clinicians. The same clinician evaluates each participant throughout. Safety is closely monitored by tracking adverse events, treatment-emergent adverse events, and serious adverse events over the full 36 months. Participants also need a support person to accompany them for some visits, ensuring safety and adherence.

Age: 40Years - 85YearsAll GendersPhase 2Phase 3
29 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of CREXONT, an extended-release capsule containing Carbidopa and Levodopa, in people with Parkinson disease PD under real-world conditions. This Phase 4 study aims to understand how well CREXONT works in reducing motor symptom fluctuations in participants who are already treated with stable oral Carbidopa-Levodopa regimens. Participants will receive CREXONT extended-release capsules orally, with doses guided by FDA-approved prescribing information. The capsules come in several strengths, and dosing will be adjusted individually to find the best balance between effectiveness and tolerability. The study includes an initial dosing based on prior oral medication and allows optimization throughout the study to meet each participants needs. During the study, participants will complete Parkinsons Disease diaries to track On and Off motor states, and researchers will measure changes in Good On time and Off time by Day 42 compared to baseline. Participants will attend study visits and may receive questionnaires and assessments to monitor their condition and treatment response. The study is open-label, meaning all participants receive CREXONT, and the total participation duration includes baseline and follow-up assessments through Day 42.

Age: 18Years +All GendersPhase 4
27 locations

1-10 of 121

1